Pancreatic Cancer Research

ResearcherGunma UniversityActive in the last 2 years

Akira Watanabe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4380-9729; OpenAlex author ID A5032592447. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper

Papers 11

  1. Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancer. Co-author DOI 10.1111/cas.16087↗
  2. Usefulness of serum creatinine and cystatin C ratio as a screening tool for predicting prognosis in patients with pancreatic cancer. First author DOI 10.1002/ags3.12671↗
  3. High RRN3 expression is associated with malignant characteristics and poor prognosis in pancreatic cancer. Co-author DOI 10.1007/s10147-023-02342-w↗
  4. D-Dimer Could Be a Surrogate Postoperative Prognostic Marker of Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001537↗
  5. Long-term survival of two patients with pancreatic cancer after resection of liver and lung oligometastases: a case report. Co-author DOI 10.1186/s40792-020-01029-y↗
  6. High Co-expression of Large Tenascin C Splice Variants in Stromal Tissue and Annexin A2 in Cancer Cell Membranes is Associated with Poor Prognosis in Pancreati… Co-author DOI 10.1245/s10434-019-07708-x↗
  7. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Co-author DOI 10.1111/cas.13847↗
  8. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-017-3477-4↗
  9. High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Clinical Patients with Pancreatic Cancer. First author DOI 10.21873/anticanres.12307↗
  10. Association of RAB5 overexpression in pancreatic cancer with cancer progression and poor prognosis via E-cadherin suppression. Co-author DOI 10.18632/oncotarget.14703↗
  11. Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1. Co-author DOI 10.18632/oncotarget.22634↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Araki · 11 shared papers, 2017–2024 · strength 1.14
  2. Ken Shirabe · 11 shared papers, 2017–2024 · strength 1.14
  3. Norihiro Ishii · 9 shared papers, 2017–2024 · strength 0.96
  4. Mariko Tsukagoshi · 9 shared papers, 2017–2024 · strength 0.96
  5. Kei Hagiwara · 8 shared papers, 2018–2024 · strength 0.95
  6. Norifumi Harimoto · 8 shared papers, 2018–2024 · strength 0.95
  7. Takahiro Yamanaka · 8 shared papers, 2017–2024 · strength 0.78
  8. Takehiko Yokobori · 8 shared papers, 2017–2024 · strength 0.75
  9. Takamichi Igarashi · 6 shared papers, 2017–2020 · strength 0.46
  10. Hiroyuki Kuwano · 5 shared papers, 2017–2019 · strength 0.33
  11. Atsushi Masamune · 2 shared papers, 2019–2024 · strength 0.26
  12. Bolag Altan · 3 shared papers, 2017–2018 · strength 0.19
  13. Kiyoaki Ito · 1 shared paper, 2024 · strength 0.18
  14. Chingunjav Batbayar · 1 shared paper, 2023 · strength 0.15
  15. Kyoichi Kaira · 1 shared paper, 2018 · strength 0.07
  16. Yoshikatsu Kanai · 1 shared paper, 2018 · strength 0.07
  17. Kazunobu Suzuki · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.